Uncategorized

Otsuka picks up PTSD drug with $700M Transcend buy

Published

on

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly “paradigm-shifting therapy” in psychiatry.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version